Co-Enrollment
Clinical studies may be considered for co-enrollment into BOOST-3 as long as there is approval from the study leadership for both studies ahead of time.
Sites should consider any potential logistical concerns before a decision is made to allow for co-enrollment and should be reviewed with local Site PIs. The decision to allow co-enrollment depends on the ability to preserve the scientific integrity of both studies.
BIO-BOOST
CAVALIER/LITES Network
Electro-BOOST
Feasibility Study of a Single Platform Solution (SPS) for Blood Testing of TBI Biomarkers
MALDI (Only allowable under these circumstances – Surrogates must be approached for consent in BOOST-3 and Bio-BOST first, both in situations of them being present at the time of initial BOOST enrollment and if the patient is enrolled under EFIC and surrogates are approached after their identification / arrival.)
PACT/LITES Network
Pilot study in acquired brain injury patients exploring association of non-invasive optic nerve sheath diameter (ONSD) measurements with intracranial pressure (ICP)
Protest
TOWAR/LITES Network
TROOP
A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301), 50 mg/mL, in patients with severe Traumatic Brain Injury.
CoMind EFS
FIT-BRAIN
INDICT